Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, said: “The start of our Phase III trial investigating Pollinex Quattro Birch marks the beginning of a number of trials aimed
The report titled “Global Allergy Immunotherapy Market”, provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region. The report also assesses the
Zeus Capital’s Dr Gary Waanders discusses Allergy Therapeutics plc in this exclusive interview with DirectorsTalk
Allergy Therapeutics Plc (LON:AGY) is the topic of conversation with Dr Gary Waanders Director of Healthcare Research at Zeus Capital. Since Allergy Therapeutics announced today that it has obtained approval
Allergy Therapeutics plc (LON:AGY) Chief Scientific Officer Murray Skinner speaks to Proactive Investors about their Phase I clinical study of Acarovac MPL receiving official sign-off in Spain. A total of
Allergy Therapeutics plc (LON:AGY) is a UK-based, specialty pharmaceutical company focused on the development, manufacture and sale of vaccines and other products for the treatment and prevention of allergies. This
Commenting on the CTA approval, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, said: “By using the successful biodegradable adjuvant system of MCT(R) and MPL, integral in our seasonal
Allergy Therapeutics plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Trials to obtain full regulatory approval as a biological for its ultra short-course immunotherapy,
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Mr Jeff Barton to the Company’s Board as a Non-Executive Director, nominated
Allergy Therapeutics Plc (LON:AGY) is a UK-based, specialty pharmaceutical company focused on the development, manufacture and sale of vaccines and other products for the treatment and prevention of allergies. This
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
